Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
INTEREST in scarlet fever immunization recently has been slight because of the present mildness of the disease and its favorable response to chemotherapy and antibiotic substances, and because the number of immunizing injections required has been large and not infrequently accompanied with general reactions. New types of antigens that require fewer injections and give only negligible reactions have reawakened interest in scarlet fever immunization. The antigen used in this study was a refined, tannic acid–precipitated, aluminum hydroxide–resuspended scarlet fever streptococcus toxin U.S.P.1 that contains one-tenth the alum of alum-precipitated toxoids. This preparation is more stable than the material stabilized with pectin or acacia. Three injections of 0.1 cc. each were given at monthly intervals. The doses were as follows: For children First 750 Second 3,000 Third 10,000 For adults First 500 Second 2,000
American journal of diseases of children – American Medical Association
Published: Dec 1, 1947
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.